The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myeloma

The European Commission has granted conditional marketing authorisation for elranatamab, also known as Elrexfio® marketed by the pharmaceutical company Pfizer. This follows an earlier positive recommendation from the European Medicines Agency (EMA – the EU drug licensing body) Committee for Medicinal Products for Human Use (CHMP), after which the European Commission had 60 days to ratify. The decision means that the product is safe and effective to prescribe in myeloma patients in the 27 EU…

2023: Year in Review

On behalf of the Myeloma Patients Europe (MPE) Board of Directors and staff, we extend a heartfelt thank you to our members, sponsors and stakeholders for your dedication and inspiration.   This year, MPE achieved significant milestones made possible by our collective efforts, and we are thrilled to present our Year in Review 2023. We hope you’ll take a moment to read this report, which highlights our key accomplishments focused on empowering, educating and supporting the patient…

Myeloma and AL amyloidosis ASH 2023 preview

    The American Society of Hematology (ASH) Annual Meeting, the world’s largest haematology conference, will take place from 9 – 12 December in San Diego, United States. It is a very exciting event for the myeloma and AL amyloidosis clinical and patient community, with all the results from the latest and most important research being presented. Myeloma Patients Europe (MPE) will attend the meeting to learn and share updates about the most significant developments…

MPE launches a report focused on the impact of AL amyloidosis in quality of life

AL amyloidosis is a rare condition and limited research on patient perspectives and needs exists. With the aim to better understand patients’ experiences regarding AL amyloidosis diagnosis and treatment, and how these impact on quality of life, MPE conducted qualitative research and published the report “Health-related quality of life, diagnosis and treatment experiences of AL amyloidosis patients.” According to this report, “receiving a diagnosis of AL amyloidosis can make people feel as if they have…

ESMO 2023 | Patient Advocacy Track highlights challenges in access, caregiver support and digitalisation

35.000 people attended the European Society for Medical Oncology (ESMO) Annual Congress, held from 20 to 24 October in Madrid, Spain, where the latest data in oncology research and development was presented. Along with several updates, mostly in solid tumours, different advocacy topics were discussed as part of the Patient Advocacy Track. Myeloma Patients Europe (MPE) was represented by Kate Morgan, MPE Co-Chief Executive Officer, and Lise-lott Eriksson, MPE president who participated in one of…

MPE launches European Amyloidosis Diagnosis Pathway to promote early detection of the rare disease

Today, 26 October 2023, is World Amyloidosis Day, a day dedicated to raising awareness about the rare disease amyloidosis and the key issues and challenges for patients. A central theme for the day, organised by the Amyloidosis Alliance, alongside amyloidosis patient organisations from across the globe, is improving the diagnosis experience of patients. Amyloidosis is a group of rare, serious conditions caused by a build-up of an abnormal protein called amyloid in organs and tissues…

MPE to present at European Society for Medical Oncology (ESMO) Annual Congress 2023

Myeloma Patients Europe (MPE) will present as part of the Patient Advocacy Track at the European Society for Medical Oncology (ESMO) Annual Congress. The Congress will be held from 20 to 24 October in Madrid, Spain where the latest data in oncology research and development will be presented. Kate Morgan, MPE Co-Chief Executive Officer, and Lise-lott Eriksson, MPE Board President, will each give a talk during the patient advocacy session, “How to improve access to…

EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myeloma

On October 12, 2023, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) gave positive recommendation for the conditional marketing authorisation of elranatamab, also known as Elrexfio. The treatment will be offered as a 40 mg/ml solution for injection. Its active component, elranatamab, is a bispecific monoclonal antibody that targets the CD3 receptor on T cells and BCMA on plasma cells, including those in malignant multiple myeloma. Elranatamab is…

A statement from MPE on the situation in Israel and Gaza

MPE and our community are extremely saddened by the ongoing and devastating events in Israel and Gaza. The death of hundreds of innocent people is completely unacceptable, and our deepest sympathy goes out to everyone affected. We know our members are continuing to provide support to patients and their families during this difficult time. All myeloma patients and caregivers in Israel who need support or have concerns should contact Varda Shoham from AMEN at: